Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Kitt

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Therapeutics|March 25, 1999
Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIaT J Lorenz, F Macdonald, M M Kitt
Neuroscience|March 17, 2015
Neuroinflammation in the normal aging hippocampusR M Barrientos, M M Kitt, L R Watkins, et al.
European Journal of Cancer & Clinical Oncology|March 1, 1986
In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assayP Dodion, C Sanders, W Rombaut, et al.
European Heart Journal|November 1, 1995
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptorE M Ohman, R A Harrington, A M Lincoff, et al.
Gastroenterology|April 1, 1989
A multiclinic trial evaluating arbaprostil [15(R)-15-methyl prostaglandin E2] as a therapeutic agent for gastric ulcerA R Euler, T Popiela, G N Tytgat, et al.
JAMA|May 23, 2001
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trialJ C O'Shea, G E Hafley, S Greenberg, et al.
Neurogastroenterology and Motility|August 21, 2009
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipationM L Manini, M Camilleri, M Goldberg, et al.
American Heart Journal|December 2, 2000
Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary interventionJ C O'shea, M Madan, W J Cantor, et al.
The American Journal of Cardiology|March 23, 2000
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisM C Thel, R M Califf, B E Tardiff, et al.
Circulation|July 27, 2001
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary interventionI C Gilchrist, J C O'Shea, T Kosoglou, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Therapeutics|March 25, 1999
Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIaT J Lorenz, F Macdonald, M M Kitt
Neuroscience|March 17, 2015
Neuroinflammation in the normal aging hippocampusR M Barrientos, M M Kitt, L R Watkins, et al.
European Journal of Cancer & Clinical Oncology|March 1, 1986
In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assayP Dodion, C Sanders, W Rombaut, et al.
European Heart Journal|November 1, 1995
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptorE M Ohman, R A Harrington, A M Lincoff, et al.
Gastroenterology|April 1, 1989
A multiclinic trial evaluating arbaprostil [15(R)-15-methyl prostaglandin E2] as a therapeutic agent for gastric ulcerA R Euler, T Popiela, G N Tytgat, et al.
JAMA|May 23, 2001
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trialJ C O'Shea, G E Hafley, S Greenberg, et al.
Neurogastroenterology and Motility|August 21, 2009
Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipationM L Manini, M Camilleri, M Goldberg, et al.
American Heart Journal|December 2, 2000
Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary interventionJ C O'shea, M Madan, W J Cantor, et al.
The American Journal of Cardiology|March 23, 2000
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary ThrombosisM C Thel, R M Califf, B E Tardiff, et al.
Circulation|July 27, 2001
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary interventionI C Gilchrist, J C O'Shea, T Kosoglou, et al.
Pageof 2